CN116790823B - 同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 - Google Patents
同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 Download PDFInfo
- Publication number
- CN116790823B CN116790823B CN202311038085.8A CN202311038085A CN116790823B CN 116790823 B CN116790823 B CN 116790823B CN 202311038085 A CN202311038085 A CN 202311038085A CN 116790823 B CN116790823 B CN 116790823B
- Authority
- CN
- China
- Prior art keywords
- htlv
- pcr
- quantitative
- kit
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 75
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 title claims abstract description 58
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 title claims abstract description 56
- 238000003757 reverse transcription PCR Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 230000009977 dual effect Effects 0.000 title claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 239000000523 sample Substances 0.000 claims description 57
- 239000013612 plasmid Substances 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000013641 positive control Substances 0.000 claims description 9
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 239000013642 negative control Substances 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 3
- 239000012807 PCR reagent Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 15
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 208000000389 T-cell leukemia Diseases 0.000 abstract description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract description 3
- 241001112090 Pseudovirus Species 0.000 description 40
- 230000003321 amplification Effects 0.000 description 28
- 238000003199 nucleic acid amplification method Methods 0.000 description 28
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000012634 fragment Substances 0.000 description 9
- 108091092584 GDNA Proteins 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 125000006853 reporter group Chemical group 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001046 green dye Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 208000027912 T-cell immunodeficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000012116 immunodeficiency-related disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311038085.8A CN116790823B (zh) | 2023-08-17 | 2023-08-17 | 同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311038085.8A CN116790823B (zh) | 2023-08-17 | 2023-08-17 | 同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116790823A CN116790823A (zh) | 2023-09-22 |
CN116790823B true CN116790823B (zh) | 2023-12-08 |
Family
ID=88044995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311038085.8A Active CN116790823B (zh) | 2023-08-17 | 2023-08-17 | 同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116790823B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117074701B (zh) * | 2023-10-18 | 2024-02-20 | 中国人民解放军空军特色医学中心 | 一种gfap定量检测试剂盒及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643714A (en) * | 1986-12-31 | 1997-07-01 | Genelabs Technologies, Inc. | Method and assay for HTLV |
CN103898239A (zh) * | 2014-03-10 | 2014-07-02 | 上海艾迪康医学检验所有限公司 | 一种同管检测htlv-i和htlv-ii前病毒的引物和方法 |
CN111926118A (zh) * | 2020-08-21 | 2020-11-13 | 苏州育德扬生物技术有限公司 | 一种可同时检测艾滋病毒1、2型病毒以及人类t淋巴细胞白血病病毒1、2型的检测方法 |
-
2023
- 2023-08-17 CN CN202311038085.8A patent/CN116790823B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643714A (en) * | 1986-12-31 | 1997-07-01 | Genelabs Technologies, Inc. | Method and assay for HTLV |
CN103898239A (zh) * | 2014-03-10 | 2014-07-02 | 上海艾迪康医学检验所有限公司 | 一种同管检测htlv-i和htlv-ii前病毒的引物和方法 |
CN111926118A (zh) * | 2020-08-21 | 2020-11-13 | 苏州育德扬生物技术有限公司 | 一种可同时检测艾滋病毒1、2型病毒以及人类t淋巴细胞白血病病毒1、2型的检测方法 |
Non-Patent Citations (3)
Title |
---|
Development of Real-Time PCR Array for Simultaneous Detection of Eight Human Blood-Borne Viral Pathogens;Natalia Pripuzova等;《PLOS ONE》;第7卷(第8期);第1-12页 * |
HTLV-1 and HTLV-2 proviral load: a simple method using quantitative real-time PCR;Bruna Pedroso Tamegão-Lopes等;《Revista da Sociedade Brasileira de Medicina Tropical》;第39卷(第6期);第548-552页 * |
Natalia Pripuzova等.Development of Real-Time PCR Array for Simultaneous Detection of Eight Human Blood-Borne Viral Pathogens.《PLOS ONE》.2012,第7卷(第8期),第1-12页. * |
Also Published As
Publication number | Publication date |
---|---|
CN116790823A (zh) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116790823B (zh) | 同步检测htlv-1和htlv-2的双重定量rt-pcr检测组合物、试剂盒和方法 | |
CN112391500B (zh) | 一种用于同时检测猫细小病毒和猫艾滋病毒的荧光定量pcr检测引物、探针和试剂盒 | |
CN112063764A (zh) | 一种用于新型冠状病毒核酸检测的多重实时荧光rt-pcr引物探针组合物及试剂盒 | |
CN112739833A (zh) | 利用巢式RPA技术检测SARS-CoV-2的引物对、探针、试剂盒及其应用 | |
CN113403430A (zh) | 一种检测猪圆环病毒不同型别的三重荧光定量pcr引物组、试剂盒及应用 | |
CN114085929B (zh) | 一种用于检测非洲猪瘟病毒野毒株和疫苗株的试剂盒 | |
CN113718058A (zh) | 一种鉴别非洲猪瘟病毒的流行株和基因缺失株的引物探针组、试剂盒及其使用方法和应用 | |
CN110714097A (zh) | 一种同时检测a、b、c三组轮状病毒的方法 | |
CN114438265B (zh) | 同时检测猪德尔塔冠状病毒、呼肠孤病毒和猪嵴病毒的核酸组合物、试剂盒及检测方法 | |
CN115852058A (zh) | 一种检测猴t细胞嗜淋巴细胞病毒的引物和探针组合及其应用 | |
CN111206117A (zh) | 一种检测人类免疫缺陷病毒的试剂盒 | |
CN116103437A (zh) | Lamp检测甲流病毒、乙流病毒及呼吸道合胞病毒的试剂盒及引物组合、方法 | |
CN114540538A (zh) | 一种同时定量检测ehv-1和ehv-4的检测试剂盒及其应用 | |
CN106755567B (zh) | 猴srv病毒实时荧光定量pcr检测引物、探针、检测试剂盒和检测方法 | |
CN111500782A (zh) | 一种新型hiv-1逆转录酶耐药突变位点检测方法的建立及应用 | |
CN113215231B (zh) | 一种SARS-CoV和COVID-19病毒双重PCR检测方法 | |
CN113293235B (zh) | 一种用于蛙病毒检测的引物及其应用 | |
CN117821666A (zh) | 用于检测hiv-1的引物组及其应用和检测方法 | |
CN118308351A (zh) | CRISPR/Cas12a检测新冠病毒BA.5的crRNA、检测方法及试剂盒 | |
CN117050990A (zh) | 一种可用于混样筛查j亚群禽白血病病毒的检测引物、试剂盒及方法 | |
CN114672594A (zh) | 一种检测肠道病毒71型的引物和探针组合及其试剂盒 | |
CN118516495A (zh) | 用于鉴别FIPV和FECV的ARMS-qPCR引物组合、试剂盒及方法 | |
CN118345202A (zh) | 一种用于检测AdC68-rab.gp病毒滴度的引物探针、试剂盒和方法 | |
CN116103443A (zh) | 用于prrsv谱系1c变异株crispr检测的引物组、试剂盒及其检测方法 | |
CN117363798A (zh) | 一种同时检测三种毒株的试剂盒和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Dong Lei Inventor after: Li Reyi Inventor after: Quan Shouzhen Inventor after: Ma Yueyun Inventor after: Liang Pei Inventor after: Huang Yue Inventor after: Li Ying Inventor after: Gong Bei Inventor after: Ping Xue Inventor before: Dong Lei Inventor before: Ma Yueyun Inventor before: Li Reyi Inventor before: Quan Shouzhen Inventor before: Liang Pei Inventor before: Huang Yue Inventor before: Li Ying Inventor before: Gong Bei Inventor before: Ping Xue |
|
CB03 | Change of inventor or designer information |